Biological Dynamics, Inc., a biotechnology company focused on detecting diseases at the earliest stages, today announced participation in a series of global events to discuss industry trends and challenges, and to preview new early-stage cancer detection data based on the company’s novel Verita™ technology.
The company is featured in the following panels and presentations:
-
April 5, 2022: Chief Medical Officer Summit 360˚
Fireside Chat with Dr. Paul Billings, CEO and Director: What Therapeutic Developers Should Look for in a Diagnostic Partner
-
April 8 – 13, 2022: American Association for Cancer Research (AACR) Annual Meeting
Presentation: Detection of early-stage lung cancer using a liquid biopsy test based on extracellular vesicle proteins
Virtual poster: Blood-based Extracellular Vesicle Biomarker Test for Detection of Early-stage Pancreatic Cancer
Virtual poster: Proteomic analysis of extracellular vesicles from oncology donor samples purified using an alternating current electrokinetic microelectrode chip
Virtual poster: Blood-based extracellular vesicle biomarker test for detection of early-stage pancreatic cancer
-
May 16, 2022: American Urological Association (AUA) Annual Meeting
Presentation: Detection of Early-Stage Bladder Cancer Using Plasma Extracellular Vesicle Protein Biomarkers
-
May 25 – 29, 2022: International Society for Extracellular Vesicles (ISEV) Annual Meeting:
Presentation: Electrokinetic Isolation of Extracellular Vesicles from Pancreatic, Ovarian and Bladder Cancers Enables Early Detection
- June 21, 2022: Liquid Biopsy Panel at the Nephron Research Liquid Biopsy Innovation Symposium
-
June 30, 2022: Precision Medicine World Conference (PMWC) 2022 Silicon Valley
Liquid Biopsy Showcase: Exosome Classifier For Early-Stage Cancer Detection
Additional details can be found on the company’s Events page.
About Biological Dynamics
Biological Dynamics, Inc. is a biotechnology company committed to improving global health outcomes by detecting diseases at their earliest stages. Our proprietary Verita™ platform simplifies access to biomarkers, nanoparticles, and nucleic acids, enabling differentiated multiomic applications. We are applying our proprietary methods with machine learning to detect several diseases, including cancer, in blood and other bodily fluids, at our CAP/CLIA accredited clinical laboratory in San Diego. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005398/en/
Contacts
Kevin Han
Chief Financial Officer
kevin.han@biodyn.io
